Bristol-Myers Squibb Co (XSWX:BMY) 6-Month Price Index: 1.12 (As of Sep. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BMY Bristol-Myers Squibb Co XSWX:BMY
73 GF Score
Price CHF54.34
GF Value CHF45.75
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co 6-Month Price Index?

Bristol-Myers Squibb Co XSWX:BMY 73 6-Month Price Index is 1.12 as of Sep. 03, 2026. GuruFocus rates XSWX:BMY with a GF Score™ of 73/100 and a GF Value™ of CHF45.75 (Modestly Overvalued). The stock has 7 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-09-03), Bristol-Myers Squibb Co's 6-Month Price Index is 1.12.

Bristol-Myers Squibb Co  (XSWX:BMY) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Bristol-Myers Squibb Co 6-Month Price Index Related Terms

XSWX:BMY vs PFE, GILD, AMGN: 6-Month Price Index Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XSWX:BMY
73GF Score
Bristol-Myers Squibb Co XSWX:BMY
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co  (XSWX:BMY) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 1.12 mean?
Bristol-Myers Squibb Co (XSWX:BMY) has a 6-Month Price Index of 1.12 as of Sep. 03, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's 6-Month Price Index too high?
Bristol-Myers Squibb Co's current 6-Month Price Index is 1.12. Overall, Bristol-Myers Squibb Co has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's 6-Month Price Index compare to PFE and GILD?
Bristol-Myers Squibb Co's 6-Month Price Index of 1.12 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Drug Manufacturers company?
A good 6-Month Price Index depends on the Drug Manufacturers industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current 6-Month Price Index is 1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (XSWX:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF45.75, compared to a current price of CHF54.34 — trading 18.8% above its estimated fair value. The current 6-Month Price Index is 1.12. Bristol-Myers Squibb Co's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Bristol-Myers Squibb Co (XSWX:BMY), the current 6-Month Price Index is 1.12 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (XSWX:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of CHF54.34 is trading 18.8% above its estimated GF Value™ of CHF45.75. GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.

Key valuation signals for XSWX:BMY:

  • 6-Month Price Index: 1.12
  • GF Value™: CHF45.75 vs. price of CHF54.34 (18.8% above fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
73GF Score

Get the complete analysis for XSWX:BMY

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF54.34
Price
CHF45.75
GF Value